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Urine glyceraldehyde excretion is elevated in the renal Fanconi syn-
drome. We analyzed urinary constituents using GC/MS in 16 children
with the renal Fanconi syndrome and 13 normal individuals. Urine
glyceraldehyde levels were strikingly elevated in the renal Fanconi
syndrome group (mean 5.1 4.8 mg/mg creatinine) compared to levels
in the normal group (mean 0.04 0.04 mg/mg creatinine, P < 0.001).
Urine lactate levels were also elevated in the renal Fanconi syndrome
group (mean 2.3 2.6 mg/mg creatinine) compared to normals (mean
0.01 0.01 mg/mg creatinine, P < 0.003). Only small elevations of
glyceraldehyde and lactate were found in urine from children with other
renal disorders. Serum levels of glyceraldehyde and lactate were no
greater in individuals with the Fanconi syndrome than in the normals.
The fractional reabsorption of both glyceraldehyde and lactate was
virtually complete in the normals, but was markedly impaired in the
Fanconi syndrome patients where, in some cases, glyceraldehyde
excretion greatly exceeded the excretion of creatinine. We conclude
that marked glyceraldehyde excretion is a previously unrecognized
feature of the renal Fanconi syndrome which may result from disor-
dered proximal tubular glycolytic metabolism. Further studies will be
required to determine the role of glyceraldehyde loss in the pathogen-
esis of this generalized disturbance of proximal tubular function.
The renal Fanconi syndrome is a generalized disturbance of
proximal tubular function which is characterized by the loss of
a variety of solutes including electrolytes, minerals, sugars,
carnitine, small proteins, and amino acids [1—5]. Affected indi-
viduals may have electrolyte imbalance, acidosis, and meta-
bolic bone disease. This collection of renal transport problems
is associated with several inherited disorders of metabolism,
disordered antibody production, and exposure to a number of
drugs and toxins [2,4, 6—22]. Treatment of underlying disorders
or avoidance of offending drugs or toxins may result in im-
proved renal tubular function. Otherwise, treatment is com-
prised of supportive measures such as electrolyte supplemen-
tation and administration of vitamin D for metabolic bone
disease. Decreased energy production in the renal proximal
tubule due to either the accumulation of metabolic poisons or
the depletion of intracellular phosphate has been proposed as a
mechanism for the development of this syndrome [4, 21—23].
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The function of a variety of energy-dependent transport sys-
tems would thus be secondarily affected.
We noted the marked excretion of glyceraldehyde in a child
with growth failure and muscle weakness whose urine was
analyzed by gas chromatography and mass spectrometry (GC/
MS) as part of a series of studies performed to establish an
etiology for her condition. She ultimately proved to be suffering
from the severe infantile form of cytochrome c oxidase deli-
ciency complicated by the renal Fanconi syndrome. We postu-
lated whether excretion of glyceraldehyde, a glycolytic inter-
mediary derived from fructose, was related to the pathogenesis
of the renal Fanconi syndrome in this patient. GCIMS analysis
was performed on urine samples from 16 individuals with the
renal Fanconi syndrome due to diverse inherited disorders of
metabolism. Our findings of elevated urine glyceraldehyde and
lactate concentrations are reported here.
Methods
Subjects
Urine was obtained from sixteen children with the renal
Fanconi syndrome including nine with nephropathic cystinosis
[2], two with poorly characterized hepatic glycogenosis and
abnormal galactose metabolism [7, 8], and one each with
tyrosinosis [11], Kearns-Sayre syndrome [24], Lowe syndrome
[12], cytochrome c oxidase deficiency [6], and idiopathic Fan-
coni syndrome. All of these patients were receiving electrolyte
solutions, supplemental phosphorus and vitamin D as part of
their therapy. Urine was also obtained from a control popula-
tion of 13 healthy individuals without a history of renal disease.
Twenty-one individuals with a variety of renal glomerular,
tubular, and anatomic disorders were studied as well. One
individual with VDRR was under treatment with calcitriol and
oral phosphate. Three individuals with RTA-4 were under
treatment with electrolyte solutions.
Sample analysis
Samples were stored at —20°C until analysis. Urine amino
acid content was determined quantitatively by automated
amino acid analysis [25]. Creatinine levels in urine and serum
were determined spectrophometrically [26].
Urine organic acids were analyzed by GC/MS. The derivati-
zation and extraction techniques are summarized as follows.
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Fig. 1. Gas chromatograms obtained
following the EO-TMS derivatization of urine
from a patient with the renal Fanconi
syndrome (A) and a 2 mg/mI aqueous
glyceraldehyde standard (B). Three isomeric
peaks (I, II, and III) are apparent in both
samples.
One ml of urine was mixed with 10 g of 4-chlorobenzoic acid
as an internal standard. The solution was alkalinized with 100 d
of 6 N NaOH, mixed with 500 d of pyridine containing 50 mg of
ethoxylamine HCI, and heated to 60°C for 30 minutes. After
cooling to room temperature, 250 s1 of N-trimethylsilyl imid-
azole was added and the heating step was repeated. The
solution was again cooled to room temperature, adjusted to pH
I using 6 N HC1, saturated with NaC1, and extracted with ethyl
acetate. The organic layer was removed and dried under
nitrogen. Silylation was repeated using 150 l of bis-(trimethyl-
silyl)-tri-fluroacetamide and heating to 80°C for 60 minutes.
Ethyloxime-trimethlysilyl (EO-TMS) derivatives were sepa-
rated on a 60 m x 0.32 mm Durabond DB-1 fused silica capillary
column with a 1.0 m polymethyl siloxane bonded liquid phase.
Analysis of the column effluent was performed using a Finni-
gan-MAT model 1020 GC/MS Auto-Quan and an electron
impact ion source.
Results
Identification of glyceraldehyde
The gas chromatography profiles of a urine sample from a
patient with the renal Fanconi syndrome and an aqueous
glyceraldehyde standard (2.0 mglml) are compared in Figure 1.
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Fig. 2. Identical mass spectra obtained from the analysis of peak II in the Fanconi syndrome urine (A) and the glyceraldehyde standard (B).
Three isomeric peaks, designated I, II, and III, were observed
following the EO-TMS derivatization of both the glyceral-
dehyde standard and the Fanconi syndrome urine. The reten-
tion times of the isomeric peaks varied by no more than 2%
between the glyceraldehyde standard and the patient sample. In
Figure 2, the mass spectra of peak II from the glyceraldehyde
standard and the patient sample are shown to be identical. Since
peak II was the major isomer, this was used for subsequent
quantitation.
The addition to normal urine of millimolar concentrations of
glucose, galactose, fructose, B-glycerophosphate, glycerol, and
glyceric acid, all potential sources of glyceraldehyde, had no
effect on glyceraldehyde levels (data not shown). Thus, the
detection of glyceraldehyde in Fanconi syndrome urine does
not appear to be a consequence of degradative processes
occurring during analysis.
Patient data
Clinical information concerning the individuals with the renal
Fanconi syndrome is presented in Table 1. Serum creatinine
values ranged between 0.5 and 2.5 mgldl while ages ranged
between 2 months and 6.0 years. Urine glyceraldehyde levels
were markedly increased in the renal Fanconi syndrome pa-
tients, averaging 5.1 4.8 mg/mg creatinine (mean SD)
compared to 0.04 0.04 mg/mg creatinine in the normal group.
Three of the four Fanconi syndrome individuals with lesser
glyceraldehyde excretion (patients number 1, 4, 10 and 11) had
mild tubular dysfunction without evidence of glycosuria or
proteinuria. Urine lactate levels were elevated in the renal
Fanconi syndrome patients, averaging 2.3 mg lactate/mg creat-
mine 2.6 (mean SD) as opposed to 0.01 mg lactate/mg
creatinine 0.01 for the normal group.
Urine glyceraldehyde and lactate levels were measured in 21
individuals with a variety of renal disorders (Table 2). Levels of
both compounds were lowest in those individuals with inher-
ited, specific disorders of proximal tubular transport (Group I).
While urine glyceraldehyde and lactate levels were increased in
association with other types of renal disease (Groups II to IV),
these levels were considerably lower than the mean levels in the
Fanconi syndrome group (Table 3).
Fractional reabsorption
Serum lactate and glyceraldehyde levels were measured by
GC/MS in three renal Fanconi syndrome patients and four
normal individuals (Table 4). The serum levels of these sub-
stances in the Fanconi syndrome patients were somewhat lower
than in the normal group. The fractional reabsorption of lactate
and glyceraldehyde was virtually complete in the normals
(Table 5). The reabsorption of glyceraldehyde was markedly
impaired in the Fanconi syndrome patients and, in two cases,
glyceraldehyde was excreted in excess of creatinine. Lactate
reabsorption was also impaired in patients with the Fanconi
syndrome, although lactate excretion did not surpass that of
creatinine.
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Table 1. Urine glyceraldehyde and lactate concentrations in the renal Fanconi syndrome
Age Creatinine Glyceraldehyde
Diagnosis years serum p.g/mg Cr
Lactate
1 cystinosis 3 0.4 108 6,573
2 cystinosis 6 2.5 1,652 210
3 cystinosis 8 2.4 10,070 3,660
4 cystinosis 4 0.6 364 113
5 cystinosis 7 1.3 1,724 383
6 cystinosis 4 0.6 11,425 3,754
7 cystinosis 7 2.2 3,636 3,080
8 cystinosis 6 1.5 4,931 541
9 cystinosis 4 1.0 5,633 3,813
10 Kearns-Sayre ii 0.7 252 934
11 Lowe Syndrome 5 0.5 189 7
12 tyrosinosis 1 0.1 3,706 8,348
13 cyt c. oxidase 1 0.5 12,734 4,128
14 glycogenosis 1 0.6 7,534 67
15 glycogenosis 1 0.4 14,615 121
16 idiopathic 1 0.5 2,862 1,007
Fanconi syndrome Mean SD 5,089 4,810 2,296 2,575
N = 16
Normals N = 13 Ages 1-43 yrs Mean SD 35 36
Table 2. Urine glyceraldehyde and lactate levels in renal disease
11 8
Group
Age Glyceraldehyde
Diagnosis years p.g/mg Cr
Lactate
I VDRR 4 4 10
Proximal VDRR 26 96 15
tubular Cystinuria 8 78 30
disorders Hartnup disease 3 13
Groupmean±sD 48±46
16
18±9
II FSGS, nephrotic synd 8 315 30
Glomerular FSGS, nephrotic synd 11 380 463
disorders FSGS, nephrotic synd 16 15
FSGS, tubular atrophy 17 0
DPGN, tubular atrophy 17 105
MesPGN, nephrotic synd 7 6
Group mean SD 137 169
6
23
22
314
143 196
III
Distal
tubular
RTA-4 3 322
RTA-4 4 71
RTA-4 2 189
37
9
7
disorders Group mean SD 194 126 18 17
IV Reflux 6 388 30
Miscellaneous Reflux nephropathy 16 44
Rellux, UPJ obstruction 22 82
Interstitial nephritis 13 262
Recurrent UTI's 17 58
Orthostatic proteinuria 10 70
Microscopic hematuria 4 113
Renal transplant 22 116
Group mean SD 142 121
16
39
10
16
13
41
35
25 13
Total N = 21 3—27 yrs
mean SD 130 127 56 113
glomcrulosclerosis; DPGN, diffuse proliferativeAbbreviations are: VDRR, x-linked hypophosphatemic rickets; FSGS, focal segmental
glomerulonephritis; MesPGN, mesangial proliferative glomerulonephritis.
Discussion analysis. This may explain why the urinary excretion of glyce-
The method we have employed for the GC/MS analysis of raldehyde has not been recognized as a general feature of the
urine is particularly well suited for the detection of water renal Fanconi syndrome, although it has been reported in an
soluble compounds, such as glyceraldehyde, which may other- isolated case of a child with tyrosinosis [271. Urine glyceral-
wise be lost during usual extraction procedures preceding dehyde and lactate excretion in the renal Fanconi syndrome
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Table 3. Urine glyceraldehyde and lactate levels
Glyceraldehyde Lactate
mg/mg creatinine
Normal 0.04 0.04 0.01 0.01
N = 13,
mean SD
Fanconi 5.1 4.8 (P<O.001)a 2.3 2.6 (P<0.003)a
syndromeN = 16,
mean SD
Other renal 0.13 0.13 0.06 0.11
disease
N = 21,
mean SD
a Determined by Student's t-test
Table 4. Serum lactate and glyceraldehyde levels
Glyceraldehyde Lactate
Diagnosis jtg/mI
Cystinosis 98 224
Cyt C oxidase 21 46
Glycogenosis 14 44
Normals 133 59 268 140
mean SD, N = 4
Table 5. Fractional reabsorption
Glyceraldehyde Lactate
Diagnosis %
Cystinosis 43 83
Cyt C oxidase 502 10
Glycogenosis 223' 99
Normals 100 0.1 100 0.1
(mean SD, N = 4)
a fractional excretion
appears unrelated to either increased serum levels of these
substances, administration of electrolyte solutions, or inciden-
tal formation during derivatization procedures. Rather, excre-
tion of glyceraldehyde and lactate seems directly related to
renal proximal tubular dysfunction.
Only free glyceraldehyde is detected by GC/MS since phos-
phorylated compounds are not sufficiently volatile to pass
through the gas chromatograph. Rodent studies indicate that
free-glyceraldehyde is produced intracellularly (Fig. 3) predom-
inantly by the action of aldolase on fructose 1-phosphate
[28—301. The reversible nature of the aldolase reaction is dem-
onstrated by the accumulation of fructose 1-phosphate when rat
hepatocytes are incubated with glyceraldehyde [31]. Glyceral-
dehyde is subsequently phosphorylated in a Mg/ATP depen-
dent, rate limiting step by the action of triokinase, an enzyme
which is quite sensitive to the inhibitory effects of ADP [29].
The release of glyceraldehyde by rat kidney infused with
fructose solutions attests to the rate limiting properties of the
triokinase step [321.
Decreased energy production has been suggested as a cause
of the renal Fanconi syndrome, based on investigation of animal
G lycogen
Glucose Glucose 6-P
Fructose Fructose 6-Pl
Fructose 1-P Fructose 1, 6-diP
i i Dihydroxyacetone-P
Glyceraldehyde Glyceraldehyde 3.p
models and hereditary fructose intolerance in man [2 1—23, 33—
36]. A model of aberrant energy production and altered redox
potential in the renal proximal tubule can be used to explain
lactate and glyceraldehyde excretion. For example, in cyto-
chrome c oxidase deficiency, defective electron transport may
lead to an elevated NADH/NAD ratio and a decreased ATP/
ADP ratio. Elevated intracellular ADP concentrations would
predispose to increased pyruvate production by stimulating
phosphofructokinase activity. Since NADH is also present in
excess, this would shift the equilibrium towards lactate produc-
tion similar to what occurs during tissue hypoxia. Free-glycer-
aldehyde derived from dietary fructose intake would accumu-
late due to inhibition of triokinase by ADP. Ultimately, the
concentration gradient across proximal tubular cells would
cause lactate and glyceraldehyde to appear in urine. It is
interesting to speculate that fructose 1-P might also accumulate
through reversal of the aldolase reaction. In studies of heredi-
tary fructose intolerance where aldolase activity is deficient,
fructose 1-phosphate accumulation results in the renal Fanconi
syndrome due in part to decreased intracellular inorganic
phosphorus and destruction of nucleotides by activation of
adenine deaminase. Thus, it is conceivable that fructose intake
in individuals with the renal Fanconi syndrome due to other
disorders might exacerbate already disordered renal tubular
metabolism. This issue merits additional study.
Glyceraldehyde excretion may be a useful marker for the
diagnosis of the renal Fanconi syndrome. Indeed we have only
found elevated urinary glyceraldehyde under one other condi-
tion, following severe hypoxia associated with transient cardio-
pulmonary arrest. As previously discussed, hypoxia would also
fit with our proposed mechanism of glyceraldehyde excretion.
Our findings suggest that aberrant glycolysis due to altered
cellular NAD and ATP concentrations may be a general mech-
anism in the evolution the renal Fanconi syndrome. Future
studies of human and animal models may provide more infor-
mation concerning both the mechanism of glyceraldehyde and
lactate excretion, and its relationship to the development of
generalized proximal tubular dysfunction.
lv
Lactate Pyruvate
NAD NADH
Fig. 3. Glycolytic pathways. Some steps have been abbreviated. I-
phosphofructokinase (ADP stimulated), II = fructose aldolase, III-
triokinase (ADP inhibited), IV = lactate dehydrogenase.
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